{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T18:04:39Z","timestamp":1743962679357},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,6,14]],"date-time":"2007-06-14T00:00:00Z","timestamp":1181779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2007,8,9]]},"DOI":"10.1007\/s11864-007-0019-z","type":"journal-article","created":{"date-parts":[[2007,6,14]],"date-time":"2007-06-14T06:29:05Z","timestamp":1181802545000},"page":"74-88","source":"Crossref","is-referenced-by-count":14,"title":["Chemoprevention Strategies 2006"],"prefix":"10.1007","volume":"8","author":[{"given":"Victor G.","family":"Vogel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,14]]},"reference":[{"key":"19_CR1","first-page":"87s","volume":"19","author":"VG Vogel","year":"2001","unstructured":"Vogel VG: Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol 2001, 19:87s\u201392s","journal-title":"J Clin Oncol"},{"key":"19_CR2","volume-title":"Handbook of breast cancer risk assessment: evidence-based guidelines for evaluation, prevention, counseling, and management","year":"2003","unstructured":"Vogel VG, Bevers T (eds.): Handbook of breast cancer risk assessment: evidence-based guidelines for evaluation, prevention, counseling, and management. Jones and Bartlett Publishers, Boston, 2003"},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Brinton LA, Byar DP, et al.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81:1879\u20131886","journal-title":"J Natl Cancer Inst"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/dc.20004","volume":"30","author":"V Vogel","year":"2004","unstructured":"Vogel V: Atypia in the assessment of breast cancer risk: implications for management. Diagn Cytopathol 2004, 30:151\u2013157","journal-title":"Diagn Cytopathol"},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/jnci\/91.18.1541","volume":"91","author":"JP Costantino","year":"1999","unstructured":"Costantino JP, Gail MH, Pee D, et al.: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999, 91:1541\u20131548","journal-title":"J Natl Cancer Inst"},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/jnci\/93.5.358","volume":"93","author":"B Rockhill","year":"2001","unstructured":"Rockhill B, Spiegelman D, Byrne C, et al.: Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001, 93:358\u2013366","journal-title":"J Natl Cancer Inst"},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","volume":"17","author":"R Day","year":"1999","unstructured":"Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B: Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999, 17:2659\u20132669","journal-title":"J Clin Oncol"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.2002.06.029","volume":"20","author":"RT Chlebowski","year":"2002","unstructured":"Chlebowski RT, Col N, Winer EP, et al.: American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002, 20:3328\u20133343","journal-title":"J Clin Oncol"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00689678","volume":"31","author":"TJ Powles","year":"1994","unstructured":"Powles TJ, Jones AL, Ashley SE, et al.: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 1994, 31:73\u201382","journal-title":"Breast Cancer Res Treat"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371\u20131388. This is the largest, prospective, randomized clinical trial of tamoxifen for breast cancer risk reduction ever conducted, and it established tamoxifen as an effective agent for reducing the incidence of both invasive and in\u00a0situ breast cancer in high-risk women","journal-title":"J Natl Cancer Inst"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S0140-6736(02)08159-X","volume":"359","author":"U Veronesi","year":"2002","unstructured":"Veronesi U, Maisonneuve P, Sacchini V, et al.: Tamoxifen for breast cancer among hysterectomised women. Lancet 2002, 359:1122\u20131124","journal-title":"Lancet"},{"key":"19_CR12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","volume":"360","author":"IBIS Investigators","year":"2002","unstructured":"IBIS Investigators: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360:817\u2013824","journal-title":"Lancet"},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","volume":"361","author":"J Cuzick","year":"2003","unstructured":"Cuzick J, Powles T, Veronesi U, et al.: Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361:296\u2013300. A thorough review of all of the tamoxifen risk reduction trials","journal-title":"Lancet"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3233\/BD-2006-24107","volume":"24","author":"BA Geller","year":"2005-2006","unstructured":"Geller BA, Vogel VG. Chemoprevention of breast cancer in postmenopausal women. Breast Disease 2005\u20132006, 24:79\u201392","journal-title":"Breast Disease"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/jnci\/93.21.1615","volume":"93","author":"R Day","year":"2001","unstructured":"Day R, Ganz PA, Costantino JP: Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project\u2019s Breast Cancer Prevention (P-1) randomized study. J Natl Cancer Inst 2001, 93:1615\u20131623","journal-title":"J Natl Cancer Inst"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jnci\/95.2.160","volume":"95","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Maisonneuve P, Rotmensz N, et al.: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003, 95:160\u2013165","journal-title":"J Natl Cancer Inst"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer J, Duffy SW, Cuzick J.: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004, 23:1111\u20131130","journal-title":"Stat Med"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","volume":"91","author":"MH Gail","year":"1999","unstructured":"Gail MH, Costantino JP, Bryant J, et al.: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999, 91:1829\u20131846. A comprehensive review of the risks and benefits of tamoxifen for reducing the risk of breast cancer. It contains exhaustive tables classified by age and race to estimate net benefits of tamoxifen therapy","journal-title":"J Natl Cancer Inst"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7326\/0003-4819-137-1-200207020-00017","volume":"137","author":"LS Kinsinger","year":"2002","unstructured":"Kinsinger LS, Harris R, Woolf SH, et al.: Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137:59\u201369","journal-title":"Ann Intern Med"},{"key":"19_CR20","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"M-C King","year":"2001","unstructured":"King M-C, Wieand S, Hale K, et al.: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA 2001, 286: 2251\u20132256","journal-title":"JAMA"},{"key":"19_CR21","first-page":"139","volume":"3","author":"VG Vogel","year":"2007","unstructured":"Vogel VG: Raloxifene: a second-generation selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women. Women\u2019s Health 2007, 3:139\u2013153","journal-title":"Women\u2019s Health"},{"key":"19_CR22","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281:2189\u20132197","journal-title":"JAMA"},{"key":"19_CR23","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E, et al.: Continuing outcomes relevant to evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96:1751\u20131761","journal-title":"J Natl Cancer Inst"},{"key":"19_CR24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, et al.: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355:125\u2013137","journal-title":"N Engl J Med"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, et al.: Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006, 295 :2727\u20132741. A randomized comparison of tamoxifen to raloxifene in postmenopausal women who were at increased risk of breast cancer. Raloxifene was as effective as tamoxifen in reducing the incidence of invasive breast cancer with substantially fewer benign and malignant uterine events and one-third fewer thrombotic events","journal-title":"JAMA"},{"key":"19_CR26","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1001\/jama.295.23.joc60075","volume":"295","author":"SR Land","year":"2006","unstructured":"Land SR, Wickerham DL, Costantino JP, et al.: Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2742\u20132751","journal-title":"JAMA"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jnci\/95.7.526","volume":"95","author":"AN Freedman","year":"2003","unstructured":"Freedman AN, Graubard BI, Rao SR, et al.: Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003, 95:526\u2013532","journal-title":"J Natl Cancer Inst"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-007-0019-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-007-0019-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-007-0019-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:34:16Z","timestamp":1559432056000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-007-0019-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,14]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,8,9]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s11864-007-0019-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,14]]}}}